PharmacoEconomics
1997 - 2025
Current editor(s): Timothy Wrightson and Christopher I. Carswell From Springer Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing (). Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.
Volume 43, issue 6, 2025
- Using AI in the Economic Evaluation of AI-Based Health Technologies pp. 597-600

- Salah Ghabri
- A Review of Heterogeneity in Comparative Economic Analysis, with Specific Considerations for the Decentralized US Setting and Patient-Centered Care pp. 601-616

- Michael S. Willis, Andreas Nilsson and Cheryl A. Neslusan
- What are the Revealed and Stated Population Preferences for Environmental Sustainability in Healthcare? A Scoping Review pp. 617-627

- Charlotte Desterbecq, Mark Harrison and Sandy Tubeuf
- Correction: What are the Revealed and Stated Population Preferences for Environmental Sustainability in Healthcare? A Scoping Review pp. 629-629

- Charlotte Desterbecq, Mark Harrison and Sandy Tubeuf
- Economic Evaluation of Interventions to Reduce Antimicrobial Resistance: A Systematic Literature Review of Methods pp. 631-646

- Kristina Aluzaite, Marta O. Soares, Catherine Hewitt, Julie Robotham, Chris Painter and Beth Woods
- Artificial Intelligence as a New Research Ally? Performing AI-Assisted Systematic Literature Reviews in Health Economics pp. 647-650

- Sietse Mossel, Martijn Johan Oude-Wolcherink, Rafael Emilio Feria Cardet, Lioe-Fee Geus-Oei, Dennis Vriens, Hendrik Koffijberg and Sopany Saing
- Market and Non-Market Productivity Losses Associated with Invasive Meningococcal Disease in the USA pp. 651-664

- Hiral Anil Shah, Ginita Jutlla, Oscar Herrera-Restrepo, Jonathan Graham, Mei Grace, Shah Alam Khan, Elise Kuylen, Shahina Begum, Frederik Verelst and Zeki Kocaata
- Making Composite Time Trade-Off Sensitive for Worse-than-Dead Health States pp. 665-675

- Michał Jakubczyk, Bram Roudijk, Stefan A. Lipman and Peep Stalmeier
- The Monetary Value of a Statistical Life in the Context of Atherosclerotic Cardiovascular Disease pp. 677-689

- Jorge-Eduardo Martínez-Pérez, Fernando-Ignacio Sánchez-Martínez, José-María Abellán-Perpiñán and Domingo Pascual-Figal
Volume 43, issue 5, 2025
- Uncertainty in Matching-Adjusted Indirect Comparisons Using Real-World Evidence: Evidence Assessment Group Perspective pp. 469-472

- Cyril Onwuelazu Uteh, Eugenie Evelynne Johnson, Tomos Robinson, Najmeh Moradi, Alex Inskip, Fiona R. Beyer, Katie Thomson and Gurdeep S. Sagoo
- A Taxonomy for Assessing Whether HRQoL Value Sets Are Obsolete pp. 473-481

- Richard Norman, Bram Roudijk, Marcel Jonker, Elly Stolk, Saskia Knies, Raoh-Fang Pwu, Ciaran O’Neill, Kirsten Howard and Nancy Devlin
- Towards Recommendations for Cost-Effectiveness Analysis of Predictive, Prognostic, and Serial Biomarker Tests in Oncology pp. 483-497

- Astrid Kramer, Lucas F. Schaik, Daan Broek, Gerrit A. Meijer, Iñaki Gutierrez Ibarluzea, Lorea Galnares Cordero, Remond J. A. Fijneman, Marjolijn J. L. Ligtenberg, Ed Schuuring, Wim H. Harten, Veerle M. H. Coupé and Valesca P. Retèl
- Examining Consistency Across NICE Single Technology Appraisals: A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria pp. 499-508

- Jeremiah Donoghue, Matthew Youngs, Alex Reeve, Krishna Vydyula, Natalia Kunst, Roochi Trikha and Daniel Gallacher
- Prognostic Testing for Prostate Cancer—A Cost-Effectiveness Analysis Comparing a Prostatype P-Score Biomarker Approach to Standard Clinical Practice pp. 509-520

- Adam Fridhammar, Oskar Frisell, Karin Wahlberg, Emelie Berglund, Pontus Röbeck and Sofie Persson
- Acceptance of Evidence Transfer Within German Early Benefit Assessment of New Drugs for Pediatric and Adolescents Target Populations pp. 521-553

- Georgia Pick, Dirk Müller and Charalabos-Markos Dintsios
- EQ-5D-5L or EQ-HWB-S: Which is the Better Instrument for Capturing Spillover Effects in Parental Carers of Children with COVID-19? pp. 555-567

- Wenjing Zhou, Bo Ding, Jan Busschbach, Michael Herdman, Zhihao Yang and Yanming Lu
- Cost-Effectiveness Analysis of Nirsevimab for Preventing Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease in Dutch Infants: An Analysis Including All-Infant Protection pp. 569-582

- Florian Zeevat, Simon Pol, Alexia Kieffer, Maarten J. Postma and Cornelis Boersma
- Innovative Payment Models for Sickle-Cell Disease Gene Therapies in Medicaid: Leveraging Real-World Data and Insights from CMMI’s Gene Therapy Access Model pp. 583-594

- Antal Zemplenyi, Jim Leonard, Garth C. Wright, Michael J. DiStefano, Kavita Nair, Kelly E. Anderson and R. Brett McQueen
- Correction: De Novo Cost‑Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation pp. 595-596

- Peter Gal, Gyorgyi Feldmajer, Margarida Augusto, Ray Gani, Emma Hook, Ash Bullement, Zoe Philips and Inger Smith
Volume 43, issue 4, 2025
- A Framework for Using Cost-effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals in a Context of Evolving Treatments, Prices, and Evidence pp. 363-373

- Beth Woods, Alfredo Palacios and Mark Sculpher
- Projections of Public Spending on Pharmaceuticals: A Review of Methods pp. 375-388

- Irina Odnoletkova, Patrice X. Chalon, Stephan Devriese and Irina Cleemput
- How Does Bereavement Affect the Health-Related Quality of Life of Household Members Who Do and Do Not Provide Unpaid Care? Difference-in-Differences Analyses Using the UK Household Longitudinal Survey pp. 389-402

- Becky Pennington, Mónica Hernández Alava and Mark Strong
- Value of Innovative Multiple Myeloma Treatments from Patient and Healthcare Provider Perspectives: Evidence from a Discrete Choice Experiment pp. 403-414

- Sakil Syeed, Chia Jie Tan, Amandeep Godara, Kyna Gooden, Derek Tang, Samantha Slaff, Yu-Hsuan Shih, Surachat Ngorsuraches and Nathorn Chaiyakunapruk
- Value-Based Indication-Specific Pricing and Weighted-Average Pricing: Estimated Price and Cost Savings for Cancer Drugs pp. 415-427

- Daniel Tobias Michaeli and Thomas Michaeli
- Cost Effectiveness of Exclusionary EGFR Testing for Taiwanese Patients Newly Diagnosed with Advanced Lung Adenocarcinoma pp. 429-440

- Huang-Tz Ou, Jui-Hung Tsai, Yi-Lin Chen, Tzu-I. Wu, Li-Jun Chen and Szu-Chun Yang
- Home Urine Dipstick Screening for Bladder and Kidney Cancer in High-Risk Populations in England: A Microsimulation Study of Long-Term Impact and Cost-Effectiveness pp. 441-452

- Olena Mandrik, Chloe Thomas, Edifofon Akpan, James W. F. Catto and Jim Chilcott
- Examination of Methods to Estimate Productivity Losses in an Economic Evaluation: Using Foodborne Illness as a Case Study pp. 453-467

- Kathleen Manipis, Paula Cronin, Deborah Street, Jody Church, Rosalie Viney and Stephen Goodall
Volume 43, issue 3, 2025
- Application of Multi-level Network Meta-Regression in the NICE Technology Appraisal of Quizartinib for Induction, Consolidation and Maintenance Treatment of Newly Diagnosed FLT3-ITD-Positive Acute Myeloid Leukaemia: An External Assessment Group Perspective pp. 243-247

- Sarah J. Nevitt, David M. Phillippo, Robert Hodgson, Nicky J. Welton and Sofia Dias
- Economic Evaluations of Non-Pharmacological Interventions for Treating Disorders of Gut-Brain Interaction: A Scoping Review pp. 249-269

- Anton Pak, Madeline O’Grady, Gerald Holtmann, Ayesha Shah and Haitham Tuffaha
- Cost Effectiveness of Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma in the USA pp. 271-282

- Xiaomo Xiong and Jeff Jianfei Guo
- Unravelling the Association Between Uncertainties in Model-based Economic Analysis and Funding Recommendations of Medicines in Australia pp. 283-296

- Qunfei Chen, Martin Hoyle, Varinder Jeet, Yuanyuan Gu, Kompal Sinha and Bonny Parkinson
- A Multistate Model Incorporating Relative Survival Extrapolation and Mixed Time Scales for Health Technology Assessment pp. 297-310

- Enoch Yi-Tung Chen, Paul W. Dickman and Mark S. Clements
- Public Health Impact of Introducing a Pentavalent Vaccine Against Invasive Meningococcal Disease in the United States pp. 311-329

- Hiral Anil Shah, Ginita Jutlla, Oscar Herrera-Restrepo, Jonathan Graham, Katherine A. Hicks, Justin Carrico, Mei Grace, Diana E. Clements, Cindy Burman, Woo-Yun Sohn, Elise Kuylen, Shahina Begum and Zeki Kocaata
- Immediate Versus 5-Year Risk-Guided Initiation of Treatment for Primary Prevention of Cardiovascular Disease for Australians Aged 40 Years: A Health Economic Analysis pp. 331-349

- Jedidiah I. Morton, Danny Liew, Gerald F. Watts, Sophia Zoungas, Stephen J. Nicholls, Christopher M. Reid and Zanfina Ademi
- Cost-Effectiveness of Capivasertib as a Second-Line Therapy for Advanced Breast Cancer pp. 351-361

- Trang T. H. Nguyen and Shweta Mital
Volume 43, issue 2, 2025
- The Use of Real-World Data for Estimating Relative Treatment Effects in NICE Health Technology Assessment Submissions: A Review pp. 123-131

- Yoojung Che, Stephen Duffield and Manuel Gomes
- A Systematic Literature Review of Modelling Approaches to Evaluate the Cost Effectiveness of PET/CT for Therapy Response Monitoring in Oncology pp. 133-151

- Sietse Mossel, Rafael Emilio Feria Cardet, Lioe-Fee Geus-Oei, Dennis Vriens, Hendrik Koffijberg and Sopany Saing
- Costs of Care in Relation to Alzheimer’s Disease Severity in Sweden: A National Registry-Based Cohort Study pp. 153-169

- Sandar Aye, Oskar Frisell, Henrik Zetterberg, Tobias Borgh Skillbäck, Silke Kern, Maria Eriksdotter, Emil Aho, Xin Xia, Bengt Winblad, Anders Wimo and Linus Jönsson
- Measuring Effectiveness Based on Patient Experience (Instead of QALYs) in US Value Assessments pp. 171-176

- Maksat Jumamyradov and Benjamin M. Craig
- Recurrence of Cardiovascular Events After an Acute Myocardial Infarction in Patients with Multivessel Disease and Associated Healthcare Costs: A German Claims Data Analysis pp. 177-189

- Alexandra Starry, Nils Picker, Jonathan Galduf, Ulf Maywald, Axel Dittmar and Stefan G. Spitzer
- Value-Based Healthcare in Practice: IDEATE, a Collaboration to Design and Test an Outcomes-Based Agreement for a Medicine in Wales pp. 191-207

- Jessica R. Burton, Kate Halsby, Graciela Sáinz Fuente, Jonathan Pearson-Stuttard, Rebecca Sloan, Thomas Porter, Gareth John, Andrew Warburton, Jennifer Selby, Gail Povey, Ruhe Chowdhury, Catherine Bale, Mark Davies, Emma Clifton-Brown and Hamish Laing
- Comparison of EQ-5D-Y-3L Utility Scores Using Nine Country-Specific Value Sets in Chinese Adolescents pp. 209-221

- Ya’nan Wu, Yanjiao Xu, Zhao Shi, Junchao Feng, Zhihao Yang, Zhuxin Mao, Lei Dou and Shunping Li
- Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications pp. 223-239

- Julie A. Campbell, Glen J. Henson, Valery Fuh Ngwa, Hasnat Ahmad, Bruce V. Taylor, Ingrid Mei and Andrew J. Palmer
- Correction: Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications pp. 241-241

- Julie A. Campbell, Glen J. Henson, Valery Fuh Ngwa, Hasnat Ahmad, Bruce V. Taylor, Ingrid Mei and Andrew J. Palmer
Volume 43, issue 1, 2025
- Design and Features of Pricing and Payment Schemes for Health Technologies: A Scoping Review and a Proposal for a Flexible Need-Driven Classification pp. 5-29

- Vittoria Ardito, Oriana Ciani and Michael Drummond
- Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy pp. 31-43

- Maddalena Centanni, Janine Nijhuis, Mats O. Karlsson and Lena E. Friberg
- How Much Better is Faster? Empirical Tests of QALY Assumptions in Health-Outcome Sequences pp. 45-52

- F. Reed Johnson, John J. Sheehan, Semra Ozdemir, Matthew Wallace and Jui-Chen Yang
- Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability pp. 53-66

- Marcelien H. E. Callenbach, Rick A. Vreman, Christine Leopold, Aukje K. Mantel-Teeuwisse and Wim G. Goettsch
- The Impact of Tocilizumab Coverage on Health Equity for Inpatients with COVID-19 in the USA: A Distributional Cost-Effectiveness Analysis pp. 67-82

- Stacey Kowal and Katherine L. Rosettie
- Economic Burden Associated with Pulmonary Arterial Hypertension in the United States pp. 83-91

- Anna Watzker, Adnan Alsumali, Christine Ferro, Gabriela Dieguez, Clare Park, Dominik Lautsch and Karim El-Kersh
- Universal Health Coverage of Opioid Agonist Treatment in Norway: An Equity-Adjusted Economic Evaluation pp. 93-107

- Prayash Chaudhary, Lars Thore Fadnes, Steinar Fosse, Fatemeh Chalabianloo and Kjell Arne Johansson
- Estimating the Incremental Cost Per QALY Produced by the Spanish NHS: A Fixed-Effect Econometric Approach pp. 109-122

- Laura Vallejo-Torres
| |